IGC PHARMA, INC.: basic weighted-average shares
Basic weighted-average shares for IGC PHARMA, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All IGC PHARMA, INC. financial histories
What this measure means
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-04-01 to 2025-03-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-04-01 | 2025-03-31 | 76,517,175 | shares | 2025-06-27 | 10-K · 0001185185-25-000706 |
| 2023-04-01 | 2024-03-31 | 58,839,868 | shares | 2025-06-27 | 10-K · 0001185185-25-000706 |
| 2022-04-01 | 2023-03-31 | 52,576,258 | shares | 2024-06-24 | 10-K · 0001185185-24-000650 |
| 2021-04-01 | 2022-03-31 | 49,991,631 | shares | 2023-07-07 | 10-K · 0001185185-23-000693 |
| 2020-04-01 | 2021-03-31 | 41,963,382 | shares | 2022-06-23 | 10-K · 0001185185-22-000768 |
| 2019-04-01 | 2020-03-31 | 39,490,014 | shares | 2021-06-14 | 10-K · 0001185185-21-000802 |
| 2018-04-01 | 2019-03-31 | 35,393,407 | shares | 2020-07-13 | 10-K · 0001185185-20-000984 |
| 2017-04-01 | 2018-03-31 | 27,937,287 | shares | 2019-06-14 | 10-K · 0001185185-19-000890 |
| 2016-04-01 | 2017-03-31 | 25,658,544 | shares | 2018-06-21 | 10-K · 0001185185-18-001155 |
| 2015-04-01 | 2016-03-31 | 16,387,290 | shares | 2017-07-14 | 10-K · 0001185185-17-001544 |
| 2014-04-01 | 2015-03-31 | 14,755,893 | shares | 2016-07-14 | 10-K · 0001185185-16-004982 |
| 2013-04-01 | 2014-03-31 | 8,205,684 | shares | 2015-07-14 | 10-K · 0001185185-15-001808 |
| 2012-04-01 | 2013-03-31 | 6,966,798 | shares | 2014-07-15 | 10-K · 0001185185-14-001804 |
| 2011-04-01 | 2012-03-31 | 2,908,936 | shares | 2014-07-15 | 10-K · 0001185185-14-001791 |
| 2010-04-01 | 2011-03-31 | 15,108,920 | shares | 2012-07-16 | 10-K · 0001185185-12-001484 |
Related financial histories
- IGC PHARMA, INC.: total assets
- IGC PHARMA, INC.: total liabilities
- IGC PHARMA, INC.: stockholders equity
- IGC PHARMA, INC.: cash and cash equivalents
- IGC PHARMA, INC.: net income or loss
- IGC PHARMA, INC.: operating cash flow
- IGC PHARMA, INC.: capital expenditure payments
- IGC PHARMA, INC.: revenue
- IGC PHARMA, INC.: financing cash flow
- IGC PHARMA, INC.: investing cash flow
- IGC PHARMA, INC.: retained earnings or deficit
- IGC PHARMA, INC.: diluted weighted-average shares
- IGC PHARMA, INC.: basic earnings per share
- IGC PHARMA, INC.: diluted earnings per share
- IGC PHARMA, INC.: income tax expense or benefit
- IGC PHARMA, INC.: net property, plant and equipment
- IGC PHARMA, INC.: share-based compensation expense
- IGC PHARMA, INC.: operating income or loss
- IGC PHARMA, INC.: current assets
- IGC PHARMA, INC.: interest expense
- IGC PHARMA, INC.: current liabilities
- IGC PHARMA, INC.: current accounts payable
- IGC PHARMA, INC.: goodwill carrying amount
- IGC PHARMA, INC.: net finite-lived intangible assets
- IGC PHARMA, INC.: net current accounts receivable
- IGC PHARMA, INC.: net inventory
- IGC PHARMA, INC.: gross profit
- IGC PHARMA, INC.: cost of revenue
- IGC PHARMA, INC.: selling, general and administrative expense
- IGC PHARMA, INC.: research and development expense
Inspect the source
- Entity
- IGC PHARMA, INC. / CIK 0001326205
- Captured
- 2026-09-19T11:17:33.392Z
- SEC response SHA-256
b5e6159ba110e204ee8261b531c546158153a9053fcdb3ca873d1eff8c2a793e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001326205.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))